ArticleEpilepsy & behavior reports2026
Everolimus initiated in the neonatal period for refractory seizures associated with tuberous sclerosis complex: long-term clinical outcome.
Article in Epilepsy & behavior reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Everolimus is an established therapy for tumor manifestations and refractory focal seizures in tuberous sclerosis complex (TSC) in patients aged ≥2 years. Evidence regarding its use during the neonatal period, particularly for seizure control, remains extremely limited. Methods: We describe the clinical course, neuroimaging findings, treatment response, and developmental outcome of a neonate with genetically confirmed TSC who received early everolimus therapy for refractory seizures. Results: A term female neonate developed multifocal drug-resistant seizures beginning on day 3 of life. Brain magnetic resonance imaging demonstrated multiple cortical and subcortical tubers, and electroencephalography revealed multifocal epileptiform discharges. Despite treatment with phenobarbital, midazolam, and vigabatrin, seizures remained uncontrolled. Everolimus was initiated on day 30 of life. Seizure activity resolved completely within one week and remained controlled for over one year. The treatment was well tolerated, with no serious adverse events. Early developmental assessment at 12 months showed cognitive, language, and motor scores within the lower range of normal. Conclusion: This case suggests that early initiation of everolimus may represent a feasible adjunctive treatment option for selected neonates with TSC-associated refractory seizures.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.